Table S2. Results for measurement of serum ProGRP and NSE in the diagnosis of NEC.

Stage	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)	Positive LR	Negative LR
Total
ProGRP ≥66 ng/L	86.6	96.7	76.6	97.7	24.5	0.2
NSE ≥18 µg/L	76.3	85.2	40.4	96.4	5.2	0.3
I–II
ProGRP ≥54 ng/L	82.4	90.8	21.0	99.4	8.9	0.2
NSE ≥100 µg/L	0	100	0	97.1	–	1
ProGRP ≥66 ng/L	71.8	97.4	44.9	99.1	27.6	0.3
ProGRP ≥300 ng/L	31.8	99.9	87.1	98.0	226.3	0.7
III
ProGRP ≥64 ng/L	85.0	96.5	84.7	96.4	24.1	0.2
NSE ≥100 µg/L	9.6	100.0	0	82.6	–	0.9
ProGRP ≥66 ng/L	84.1	96.8	85.9	96.2	26.5	0.2
ProGRP ≥300 ng/L	63.4	99.7	98.1	92.1	224.5	0.4
IV
ProGRP ≥99 ng/L	83.8	98.5	90.4	97.3	54.0	0.2
NSE ≥100 µg/L	29.3	99.3	88.6	89.0	44.1	0.7
ProGRP ≥66 ng/L	86.0	95.0	74.7	97.5	17.1	0.2
ProGRP ≥300 ng/L	73.7	99.3	95.1	95.6	110.7	0.3

ProGRP, roles of gastrin-releasing peptide; NSE, neuron-specific enolase; NEC, neuro-endocrine carcinoma.